EXPEDITED REVIEW
Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine
The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial
Peter H. Stone, MD, FACC*,*,
Nikolay A. Gratsiansky, MD ,
Alexey Blokhin, MD ,
I-Zu Huang, MD ,
Lixin Meng, MS, MPH for the ERICA Investigators
* Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
Center for Atherosclerosis, Institute of Physicochemical Medicine, Moscow, Russia
Outpatient Clinic of Medical Center of Russian Federation President’s Management Department, Moscow, Russia
CV Therapeutics, Palo Alto, California
Manuscript received April 1, 2006;
revised manuscript received May 18, 2006,
accepted May 22, 2006.
* Reprint requests and correspondence: Dr. Peter H. Stone, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, Massachusetts 02115. (Email: pstone{at}partners.org).
OBJECTIVES: The purpose of this study was to determine if ranolazine improves angina in stable coronary patients with persisting symptoms despite maximum recommended dose of amlodipine.
BACKGROUND: Ranolazine is a unique antianginal agent that has been effective in stable angina, but it has not been studied in the setting of maximum recommended doses of conventional antianginal agents.
METHODS: Stable patients with coronary disease and  3 anginal attacks per week despite maximum recommended dosage of amlodipine (10 mg/day) were randomized to 1,000 mg ranolazine or placebo twice a day for 6 weeks. Primary end point was the frequency of angina episodes per week during the double-blind treatment phase. Efficacy was also assessed by nitroglycerin consumption per week and the Seattle Angina Questionnaire (SAQ). Adjustment for multiple testing of secondary end points used a hierarchic closed testing procedure. Efficacy was assessed in subgroups based on baseline angina frequency, concomitant long-acting nitrate use, gender, and age. Safety was assessed by adverse events and electrocardiogram evaluations.
RESULTS: A total of 565 patients were randomized: 281 patients to ranolazine and 284 patients to placebo. Baseline characteristics were similar between treatment groups. At baseline, angina frequency averaged 5.63 ± 0.18 episodes/week, and nitroglycerin consumption averaged 4.72 ± 0.21 tablets/week. Compared with placebo, ranolazine significantly reduced frequency of angina episodes (2.88 ± 0.19 on ranolazine vs. 3.31 ± 0.22 on placebo; p = 0.028) and nitroglycerin consumption (2.03 ± 0.20 on ranolazine vs. 2.68 ± 0.22; p = 0.014), with treatment effect that appeared consistent across subgroups. The median angina weekly episode rate at baseline was 4.5 per week. Subgroup analysis showed statistically significant reductions of angina frequency, nitroglycerin use, and SAQ angina frequency for patients with a baseline frequency >4.5 per week but only of angina frequency for those with baseline frequency  4.5 per week. Patients with more frequent angina appeared to have a more pronounced treatment effect. No hemodynamic changes were observed. Ranolazine was well tolerated.
CONCLUSIONS: Ranolazine significantly reduced frequency of angina and nitroglycerin consumption compared with placebo and was well tolerated. (The ERICA [Efficacy of Ranolazine In Chronic Angina] Trial; http://clinicaltrials.gov; NCT00091429
[ClinicalTrials.gov]
)
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | AE = adverse event | | CAD = coronary artery disease | | ERICA = Efficacy of Ranolazine In Chronic Angina trial | | LAN = long-acting nitrate | | SAQ = Seattle Angina Questionnaire |
|
This article has been cited by other articles:
|
|
|
|
 
S. R. Wilson, B. M. Scirica, E. Braunwald, S. A. Murphy, E. Karwatowska-Prokopczuk, J. L. Buros, B. R. Chaitman, and D. A. Morrow
Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
J. Am. Coll. Cardiol.,
April 28, 2009;
53(17):
1510 - 1516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Scirica, D. A. Morrow, A. Budaj, A. J. Dalby, S. Mohanavelu, J. Qin, J. Aroesty, C. M. Hedgepeth, P. H. Stone, and E. Braunwald
Ischemia Detected on Continuous Electrocardiography After Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) Trial
J. Am. Coll. Cardiol.,
April 21, 2009;
53(16):
1411 - 1421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Arnold, D. A. Morrow, K. Wang, Y. Lei, E. M. Mahoney, B. M. Scirica, E. Braunwald, D. J. Cohen, and on behalf of the MERLIN-TIMI 36 Investigators
Effects of Ranolazine on Disease-Specific Health Status and Quality of Life Among Patients With Acute Coronary Syndromes: Results from the MERLIN-TIMI 36 Randomized Trial
Circ Cardiovasc Qual Outcomes,
November 1, 2008;
1(2):
107 - 115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rastogi, V. G. Sharov, S. Mishra, R. C. Gupta, B. Blackburn, L. Belardinelli, W. C. Stanley, and H. N. Sabbah
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure
Am J Physiol Heart Circ Physiol,
November 1, 2008;
295(5):
H2149 - H2155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L. Eckhardt, T. C. Teelin, and C. T. January
Is ranolazine an antiarrhythmic drug?
Am J Physiol Heart Circ Physiol,
May 1, 2008;
294(5):
H1989 - H1991.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M Shavelle
Long term medical treatment of stable coronary disease
Heart,
November 1, 2007;
93(11):
1473 - 1477.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Scirica, D. A. Morrow, H. Hod, S. A. Murphy, L. Belardinelli, C. M. Hedgepeth, P. Molhoek, F. W.A. Verheugt, B. J. Gersh, C. H. McCabe, et al.
Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non ST-Segment Elevation Acute Coronary Syndrome: Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial
Circulation,
October 9, 2007;
116(15):
1647 - 1652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Morrow, B. M. Scirica, E. Karwatowska-Prokopczuk, S. A. Murphy, A. Budaj, S. Varshavsky, A. A. Wolff, A. Skene, C. H. McCabe, E. Braunwald, et al.
Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-ST-Elevation Acute Coronary Syndromes: The MERLIN-TIMI 36 Randomized Trial
JAMA,
April 25, 2007;
297(16):
1775 - 1783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. K. Newby and E. D. Peterson
Does Ranolazine Have a Place in the Treatment of Acute Coronary Syndromes?
JAMA,
April 25, 2007;
297(16):
1823 - 1825.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Koren, M. R. Crager, and M. Sweeney
Long-Term Safety of a Novel Antianginal Agent in Patients With Severe Chronic Stable Angina: The Ranolazine Open Label Experience (ROLE)
J. Am. Coll. Cardiol.,
March 13, 2007;
49(10):
1027 - 1034.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Cairns
Ranolazine: Augmenting the Antianginal Armamentarium
J. Am. Coll. Cardiol.,
August 1, 2006;
48(3):
576 - 578.
[Full Text]
[PDF]
|
|
|
|
